Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
2025 · 2nd Quarter (Apr 1 - June 30)
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Filed by PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 8, 2025
- Income
- Not reported
- Expenses
- $50,000.00
- Filing UUID
- 97287987-807d-4f00-b23f-0e5f76d1780e
- Termination date
- Not reported
Expense method: C
Literal source text
Lobbying issues and bill citations
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.